Determination of Dose of Antiangiogenic Multitargeted DOVITINIB (TKI258) Plus Paclitaxel in Patients With Solid Tumors
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Solid Tumors
Interventions: DRUG: Dovitinib|DRUG: Dovitinib + Paclitaxel
Sponsor: Centro Nacional de Investigaciones Oncologicas CARLOS III
Collaborators: Hospital Universitario de Fuenlabrada|M.D. Anderson Cancer Center|Hospital Universitari de Bellvitge